Longevity Startup Funding 2025-2026

What are all the funding deals in the longevity market from August 2025 to September 2026?

The table below lists every qualifying disclosed equity round identified for pure-play longevity companies between August 2025 and September 2026. We count as pure-play longevity companies businesses predominantly focused on products or services using science, medicine, or technology to extend healthy years of life, prevent age-related decline, or optimize long-term health.

Each row shows the company, what it does, its category, the deal date, funding stage, round size, region, and main investors. For a wider view of the companies, funding patterns, and opportunities shaping the sector, see our Longevity market report.

How active has fundraising been in the longevity market?

As of September 2026, fundraising in the longevity market has produced 24 disclosed equity rounds and $1.433B of capital over the 12-month study period. The dataset contains 23 unique companies, showing that almost every financing represents a different longevity business rather than repeated fundraising by a small group.

Deal flow averages 1.71 transactions per calendar month, while the median month contains 1.5 deals. The longevity market therefore produces a steady but relatively small stream of publicly visible financings.

Dollar activity is much less stable. Average monthly capital is $102.37M, while the median month is only $16.45M, meaning a handful of unusually large financings pull the average sharply upward.

The $1.433B headline should therefore not be treated as the normal financing environment for longevity startups. Excluding rounds above $50M leaves only $158.21M of disclosed capital.

For more context on the companies and financing patterns behind these totals, see our deeper analysis of the longevity market.

How concentrated has fundraising been in the longevity market?

As of September 2026, fundraising in the longevity market is extremely concentrated. Over the 12-month study period, the largest financing represents 48.84% of total disclosed capital, while the top 3 deals represent 84.77% and the top 5 reach 90.36%.

Neko Health's $700M Series C is nearly half of the entire dataset by itself. NewLimit adds another $435M, meaning those two companies together account for $1.135B of disclosed capital.

The top 10 financings reach 95.69% of all capital. The remaining 14 deals therefore matter much more as evidence of ecosystem breadth than as contributors to the headline dollar total.

This concentration changes how the longevity market should be interpreted. Aggregate capital is primarily a measure of conviction in a few scaled companies, rather than a measure of financing conditions for the typical longevity startup.

How much of the longevity funding signal is driven by outliers?

As of September 2026, most of the dollar signal in the longevity market is driven by outliers. Over the 12-month study period, only four of 24 rounds exceeded $50M, yet those financings contributed approximately 89% of total disclosed capital.

Neko Health raised $700M, NewLimit raised $435M, Life Biosciences raised $80M, and Blueprint raised $60M. Removing those four financings reduces the market from $1.433B to $158.21M.

The same distortion appears in the average round size. The average is $59.72M, while the median is only $7.75M, making the average roughly 7.7 times higher.

The median is therefore a much better benchmark for ordinary fundraising conditions. For a closer look at the companies creating these outliers, see our full longevity market report.

Is the longevity market broad with many targets, or narrow with few fundable companies?

As of September 2026, the longevity market has a reasonably broad early company funnel but a very narrow pool of companies receiving large institutional checks. Over the 12-month study period, 23 unique companies produced 24 disclosed financings, with Lucis the only company appearing twice.

The breadth is most visible below $20M. Twenty of the 24 disclosed rounds were $20M or smaller, spanning therapeutics, diagnostics, clinics, preventive platforms, consumer products, and aging-research businesses.

The capital picture is much narrower. Four financings above $50M account for approximately 89% of all disclosed dollars, so company breadth does not translate into evenly distributed financial backing.

The longevity market is therefore broad when measured by experiments and narrow when measured by conviction capital. That distinction is more useful than describing the market as simply large or small.

Is longevity mostly an early-stage formation market or a late-stage scaling market?

As of September 2026, the longevity market is an early-stage formation market by deal count but a late-stage scaling market by capital. Over the 12-month study period, Seed and Series A rounds account for most classified transactions, while early-stage capital represents only 7.31% of total disclosed dollars.

Seed is the most common stage with 13 of 24 financings, or 54.17% of all deals. Those 13 rounds raised only $64.81M, equal to 4.52% of total capital.

Late-stage rounds tell the opposite story. Series B, Series C, and Series D+ together account for $1.233B, or 86.03% of all disclosed capital, despite representing only four transactions.

Among financings with a classified stage, early-stage rounds capture only 7.83% of capital and late-stage rounds capture 92.17%. The longevity market therefore creates many experiments but concentrates most dollars behind a few validated or scaled businesses.

For more detail on where companies sit along this funding curve, explore our market report on longevity companies and financing.

Which categories attract the most investor attention in longevity?

As of September 2026, Preventive Health Platforms and Longevity Therapeutics Developers attract the most investor attention in the longevity market. Together they account for 13 of 24 disclosed deals and $1.277B over the 12-month study period.

Preventive Health Platforms lead deal count with 7 transactions, representing 29.17% of activity. The category also leads capital with $742.68M, or 51.82% of the longevity market.

Longevity Therapeutics Developers follow with 6 deals and $534.53M, representing 25.00% of transactions and 37.30% of disclosed capital. NewLimit's $435M financing is responsible for most of that dollar weight.

Diagnostics Biomarker Companies rank third by activity with 4 deals but capture only $26.40M. This suggests investors are willing to fund biomarker experimentation, but not yet at therapeutic or scaled-platform check sizes.

Which categories attract disproportionately large checks in the longevity market?

As of September 2026, Preventive Health Platforms and Longevity Therapeutics Developers attract disproportionately large checks in the longevity market. Over the 12-month study period, their capital-share-to-deal-share ratios are 1.78x and 1.49x respectively.

Preventive Health Platforms average $106.10M per round but have a median of only $6M. Neko Health's $700M Series C therefore explains most of the gap between the category's ordinary deal and its headline average.

Longevity Therapeutics Developers show the same pattern. The category averages $89.09M per financing but has a median of $7.77M because NewLimit and Life Biosciences absorb most of the capital.

Diagnostics Biomarker Companies have the lowest capital-share-to-deal-share ratio at 0.11x, followed by Healthy Aging Clinics at 0.14x. These categories generate meaningful deal activity without attracting similarly large balance sheets.

Which geographies matter most for fundraising in the longevity market?

As of September 2026, Europe and North America dominate fundraising in the longevity market. Together they represent 18 of 24 disclosed deals and 97.33% of all disclosed capital over the 12-month study period.

Europe leads on dollars with $749.38M, or 52.29% of total capital, from 7 financings. Its average round is $107.05M, but its median is only $8.50M.

North America leads on activity with 11 deals, or 45.83% of the dataset, and $645.53M of capital. Its $11M median round is the highest among regions with multiple qualifying transactions.

Asia-Pacific contributes 5 deals but only $31.30M, or 2.18% of total capital. Its 20.83% deal share therefore signals ecosystem formation much more strongly than its dollar share suggests.

For a broader view of the companies and regional opportunities behind these figures, see our longevity market analysis.

Is the longevity opportunity set broad or concentrated in one hub?

As of September 2026, the longevity opportunity set is concentrated in North America and Europe rather than in one single hub. Over the 12-month study period, those two regions account for 75% of disclosed deals and more than 97% of capital.

North America is the broader formation hub with 11 deals, while Europe produces only 7. Europe nevertheless leads capital because Neko Health alone raised $700M.

Removing Neko would reduce European capital from $749.38M to roughly $49.38M. Europe's aggregate lead therefore should not be interpreted as evidence that the typical European longevity company has better access to capital.

Asia-Pacific has five qualifying transactions but just 2.18% of capital, while the Middle East has one $7M financing. Latin America and Africa have no qualifying disclosed transactions in the dataset.

Is longevity a market of small experiments or scaled financings?

As of September 2026, the longevity market contains many small experiments but derives almost all of its dollar weight from a few scaled financings. Over the 12-month study period, 20 of 24 disclosed rounds were $20M or smaller, while four were above $50M.

Nine deals were $5M or below and another 11 were above $5M but no more than $20M. No qualifying financing landed between $20M and $50M, creating a striking missing middle in the longevity market.

Only four deals, or 16.67% of transactions, exceeded $50M. Just two deals, Neko Health and NewLimit, exceeded $100M, yet together they contribute $1.135B.

The median round is $7.75M, while the average is $59.72M. A new longevity company should therefore benchmark itself against the median and relevant category rather than against the market-wide average.

For more context on how funding size changes across different longevity business models, see our full market deck on longevity.

Who are the investors that appear the most in longevity fundraising?

As of September 2026, repeat investors are relatively uncommon in the longevity market. Over the 12-month study period, General Catalyst is the clearest repeat institutional investor, appearing in three qualifying financings across Lucis and Neko Health.

General Catalyst participated in Lucis's $8.5M Seed round, its subsequent $20M Series A, and Neko Health's $700M Series C. That gives it exposure across both companies and financing stages rather than repeated participation in only one business.

Y Combinator appears in both qualifying Lucis rounds. Ari Emanuel and Steven Bartlett also appear in two transactions each through participation in Blueprint and Neko Health.

The repeat-investor list is otherwise thin. That suggests the longevity market has not yet developed a large, clearly identifiable group of specialist investors repeatedly underwriting multiple companies across the category.

Individual investor check sizes are generally not disclosed. Investor frequency therefore measures participation and repeated conviction, not the amount of capital each investor personally contributed.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.